Topics

Latest "PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial" News Stories

22:51 EST 10th December 2019 | BioPortfolio

Here are the most relevant search results for "PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial" found in our extensive news archives from over 250 global news sources.

More Information about PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial for you to read. Along with our medical data and news we also list PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial Clinical Trials, which are updated daily. BioPortfolio also has a large database of PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial Companies for you to search.

Showing "PErsonalized TREatment High risk MAmmary Cancer PETREMAC Trial" News Articles 1–25 of 52,000+

Tuesday 10th December 2019

Therapix Biosciences Ltd TRPX Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $110

Therapix Biosciences Ltd TRPX Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augm...


Global Cognitive and Memory Enhancer Drugs Market Research Report 20122024 [Report Updated: 24052019] Prices from USD $1883

SummaryThe global Cognitive and Memory Enhancer Drugs market will reach xxx Million USD in 2019 with CAGR xx% 20192024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the re...

Ice loss from the Greenland Ice Sheet has added around 10.6 mm to the global sea level since 1992, according to a paper in Nature. The total amount lost from Greenland is close to that predicted by the IPCC for their high-end climate warming scenario. ht

Ice loss from the Greenland Ice Sheet has added around 10.6 mm to the global sea level since 1992, according to a paper in Nature. The total amount lost from Greenland is close to that predicted by the IPCC for their high-end climate warming scenario. https://go.nature.com/2Yz155T  pic.twitter.com/un2AhBrlkq


Portable Anaesthesia MachinesEMEA Market Status and Trend Report 20132023 [Published by MIReports] Prices from USD $3062

Report SummaryPortable Anaesthesia MachinesEMEA Market Status and Trend Report 20132023 offers a comprehensive analysis on Portable Anaesthesia Machines industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions ...

2019 Binge Eating Disorder Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1583

The global clinical trial report 2019 Binge Eating Disorder Clinical Trials Study provides complete list of trials completed, ongoing and planned for Binge Eating Disorder. It presents indepth analysis of Binge Eating Disorder clinical trials across markets and companies. The research work is for providing complete understanding into trends in Binge Eating Disorder. The report covers a key snapsh...

Sophiris Bio Inc SPHS Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $110

Sophiris Bio Inc SPHS Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your...

In M&A deals to build their #Cancer pipelines, @Merck agrees to buy @ArQuleInc for $2.7B, while @sanofi plans $2.5B purchase of @Synthorx : http://ow.ly/meb650xvjaX pic.twitter.com/UUKzmdj7fu

In M&A deals to build their #Cancer pipelines, @Merck agrees to buy @ArQuleInc for $2.7B, while @sanofi plans $2.5B purchase of @Synthorx : http://ow.ly/meb650xvjaX  pic.twitter.com/UUKzmdj7fu

FDA Panel Says No To CORV, ITRM For Sure Has Disappointed, ELOX, XERS On Watch

Today's Daily Dose brings you news about the FDA panel's vote on Correvio Pharma's anti-arrhythmic drug Brinavess; the near-term catalyst of Eloxx Pharma; the phase III trial results of Iterum's Sulopenem in the treatment of complicated intra-abdominal infections, and Xeris Pharma's phase II study results of ready-to-use (RTU) glucagon.

2019 Radiation Induced Nausea and Vomiting RINV Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1583

The global clinical trial report 2019 Radiation Induced Nausea and Vomiting RINV Clinical Trials Study provides complete list of trials completed, ongoing and planned for Radiation Induced Nausea and Vomiting RINV. It presents indepth analysis of Radiation Induced Nausea and Vomiting RINV clinical trials across markets and companies. The research work is for providing complete understanding into ...

Opinion: The problem of affordability will not be solved if Congress continues to succumb to questionable assertions by lobbyists claiming that excessively high drug prices are essential to maintaining biopharmaceutical innovation. https://buff.ly/2rqkKsG

Opinion: The problem of affordability will not be solved if Congress continues to succumb to questionable assertions by lobbyists claiming that excessively high drug prices are essential to maintaining biopharmaceutical innovation. https://buff.ly/2rqkKsG 

Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the ESMO Immuno-Oncology Congress 2019 in Geneva, Switzerland, December 11-14, including a poster presentation on December 12th. The poster presentation, titled “A comprehensive tumor immunogenomics platform for precision

2019 Vestibular Diseases Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1583

The global clinical trial report 2019 Vestibular Diseases Clinical Trials Study provides complete list of trials completed, ongoing and planned for Vestibular Diseases. It presents indepth analysis of Vestibular Diseases clinical trials across markets and companies. The research work is for providing complete understanding into trends in Vestibular Diseases. The report covers a key snapshot of tr...

[Comment] Angiotensin-II receptor blockade in Marfan syndrome

Because aortic root dilatation and resulting dissection are the most life-threatening problems in patients with Marfan syndrome, research has focused on mitigating the risk for these complications. Whereas surgical replacement of the dilated aorta remains the most effective intervention, medical treatment aimed at reducing aortic root growth also contributes to improved outcome. β blockers are co...

[Articles] Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial

Irbesartan is associated with a reduction in the rate of aortic dilatation in children and young adults with Marfan syndrome and could reduce the incidence of aortic complications.

Global Stainless Steel Insulated Lunch Box Market Research Report 20122024 [Report Updated: 25052019] Prices from USD $1822

SummaryThe global Stainless Steel Insulated Lunch Box market will reach xxx Million USD in 2019 with CAGR xx% 20192024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the re...

Short on protein chromatography time?

In a recent webinar, we shared some tips for improving protein purity and recovery while performing IEX chromatography; here, we focus on your time. Today’s protein researcher is pressed to deliver results faster than ever before. The less time spent on purification, the more time you will have to focus on studying your protein. Ion exchange chromatography can be used in the first steps of prot...

Home urine test helps diagnose aggressive prostate cancer

UK scientists have pioneered a simple urine test which diagnoses aggressive prostate cancer and predicts whether patients will require treatment up to five years earlier than standard clinical methods. Their latest study, published in the journal BioTechniques, shows how the ‘PUR’ (Prostate Urine Risk) test could be performed on samples collected at home, so men don’t have to come into the ...

Towards a personalised vaccine for pancreatic cancer

Vaccines work by training the immune system to recognise and kill pathogens within the body. To do this, immune cells must recognise molecules on the surface of the pathogens, called antigens. By injecting these antigens as a vaccine, the immune system can safely learn how to recognise them as foreign objects — and remember this should they be found in the body again. “Development of a preven...

Mitogen Activated Protein Kinase 8 Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $3080

Mitogen Activated Protein Kinase 8 Pipeline Review, H2 2019SummaryMitogen Activated Protein Kinase 8 c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24 pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institute...

Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia

BTG Plc Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $110

BTG Plc Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.This uptotheminute company report will help you to formulate strategies to drive your business by enabling...

Plakophilin 1 enhances MYC translation, promoting squamous cell lung cancer

Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer

Xeris Pharmaceuticals Announces Positive Topline Results From the In-clinic Stage of the Phase 2 Study of Its Developmental Ready-to-use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery

All subjects successfully self-administered a mini dose of RTU glucagon Rebound hypoglycemia observed more frequently in the placebo arm and with oral glucose tablet use Subcutaneous RTU glucagon is safe and well-tolerated Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injecta...

Cadent Therapeutics Announces Poster Presentation at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced a poster presentation of its lead cognitive disorder asset CAD-9303, a positive allosteric a novel, first-in-class, positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors. The poster, titled “NMDA Receptor P...


Quick Search

News Quicklinks